ABN AMRO Bank N.V. Sells 44,434 Shares of Merck & Co., Inc. $MRK

Key Points

• ABN AMRO Bank N.V. reduced its Merck stake by 23.2% in the first quarter, selling 44,434 shares and leaving it with 147,377 shares valued at about $17.9 million.
• Merck received multiple positive regulatory wins, including FDA approval for Keytruda/Keytruda Qlex with Gilead’s Trodelvy in advanced triple-negative breast cancer and EU approval for Keytruda plus Padcev in certain bladder cancer patients.
• The company reported solid quarterly results and raised investor appeal, beating earnings and revenue estimates, while analysts largely maintain a bullish view with a “Moderate Buy” consensus and an average target price of $128.72.

ABN AMRO Bank N.V. lessened its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,377 shares of the company's stock after selling 44,434 shares during the quarter. ABN AMRO Bank N.V.'s holdings in Merck & Co., Inc. were worth $17,889,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. in the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. during the third quarter valued at $31,000. Finally, High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after acquiring an additional 109 shares during the period. 76.07% of the stock is owned by institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Merck & Co., Inc. Trading Up 2.3%

NYSE:MRK opened at $128.35 on Friday. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $128.78. The business's 50-day moving average price is $116.08 and its two-hundred day moving average price is $114.33. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $316.99 billion, a price-to-earnings ratio of 36.15, a PEG ratio of 2.89 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analysts' expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company's revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Royal Bank Of Canada reiterated an "outperform" rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wall Street Zen raised Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, June 6th. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $128.72.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.